A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms ImadGist
- 04 Jan 2019 Planned number of patients changed from 256 to 134.
- 10 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Oct 2014 New trial record